Showing results 1 to 3 of 3
Title | Author(s) | Issue Date | |
---|---|---|---|
Continued suppression of viral markers observed following discontinuation of nucleos (t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729. Poster Presentation (SAT 448) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 | ||
Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 | ||
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects(HS) and subjects with chronic hepatitis B (CHB). Poster Presentation (SAT392) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 |